

18

 Name of Journal: *World Journal of Gastrointestinal Oncology*

ESPS Manuscript NO: 21801

Manuscript Type: EVIDENCE-BASED MEDICINE

3

Evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC)

 Cristiana Lo Nigro^{1a}, Vincenzo Ricci^{1b}, Daniela Vivenza^{1a}, Martino Monteverde^{1a}, Giuliana Strola², Francesco Lucio³, Federica Tonissi¹

 Emanuela Miraglio^{1b}, Cristina Granetto^{1b}, Mirella Fortunato⁴, Marco Carlo Merlano^{1b}

Match Overview

Match #	Source	Words	Percentage
1	Internet crawled on 30-Oct-2009 jco.ascopubs.org	174	3%
2	Internet crawled on 09-Jan-2010 www.ncbi.nlm.nih.gov	118	2%
3	CrossCheck Ricci, V., D. Vivenza, M. Monteverde, G. Strola, C. Granetto, C. Lo Nigro, and M. C. Merlano. "P-235 * Retrospective	112	2%
4	CrossCheck Seo, Yuki, Yoshiyuki Ishii, Hiroki Ochiai, Kazumasa Fukuda, Shingo Akimoto, Tetsu Hayashida, Koji Okabayashi,	110	2%
5	CrossCheck De Roock, W.. "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemoth	56	1%
6	Internet crawled on 14-Feb-2013 www.nature.com	55	1%

小提示: 只搜索中文(简体)结果, 可在 [学术搜索设置](#) 指定搜索语言

Fluorouracil, leucovorin, and oxaliplatin with and without **cetuximab** in the first-line treatment of **metastatic colorectal cancer**

ascopubs.org 中的 [HTML]

C Bokemeyer, [I Bondarenko](#), A Makhson... - Journal of Clinical ..., 2009 - jco.ascopubs.org
... 15,16 To further **evaluate** this combination, the Oxaliplatin and **Cetuximab** in First-Line ... The definition of relevant molecular characteristics of an individual **tumor** (biomarker **evaluation**) will increasingly ... 4, 2006) so that all **patients** could have at least two 8-week **evaluations**. ...

被引用次数: 1355 相关文章 所有 7 个版本 引用 保存

Impact of FcγRIIIa-FcγRIIIa polymorphisms and **KRAS** mutations on the clinical outcome of **patients with metastatic colorectal cancer** treated with **cetuximab** plus ...

researchgate.net 中的 [PDF]

F Bibeau, E Lopez-Crapez, F Di Fiore... - Journal of Clinical ..., 2009 - jco.ascopubs.org
... This study was designed to **evaluate** the influence of FcγRIIIa and FcγRIIIa polymorphisms and **KRAS** mutations on the outcome of 69 ... **Tumor response** was **evaluated** every 2 to 3 months by computerized tomodensitometry according to the **Response Evaluation** Criteria in ...

被引用次数: 327 相关文章 所有 9 个版本 引用 保存

[HTML] Association of **KRAS** p. G13D mutation with outcome in **patients** with chemotherapy-refractory **metastatic colorectal cancer** treated with **cetuximab**

jamanetwork.com 中的 [HTML]

W De Roock, DJ Jonker, [F Di Nicolantonio](#)... - Jama, 2010 - archophpt.jamanetwork.com
Research from JAMA — Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab.

被引用次数: 485 相关文章 所有 28 个版本 引用 保存

Clinical relevance of EGFR-and **KRAS**-status in **colorectal cancer patients** treated with monoclonal antibodies directed against the EGFR

researchgate.net 中的 [PDF]

V Heinemann, S Stintzing, T Kirchner, S Boeck... - Cancer treatment ..., 2009 - Elsevier

[网页](#)[图片](#)[新闻](#)[视频](#)[更多 ▾](#)[搜索工具](#)

找到约 59,000 条结果 (用时 0.70 秒)

P-235 * Retrospective evaluation of ADCC activity and ...

annonc.oxfordjournals.org/content/26/suppl_4/iv68.3 - 翻译此页

作者: V Ricci - 2015

2015年7月1日 - P-235. Retrospective **evaluation** of ADCC **activity** and **cetuximab** response in **KRAS wild-type metastatic colorectal cancer patients (mCRC)** ... of **cetuximab** is thought to include **antibody-dependent cell-mediated cytotoxicity (ADCC)**. **Cetuximab** has been restricted to **mCRC patients (pts)** with **wild-type RAS**.

P-235 Retrospective evaluation of ADCC activity and ...

annonc.oxfordjournals.org/content/26/suppl_4/iv68.3.full.pdf - 翻译此页

作者: V Ricci - 2015

response in **KRAS wild-type metastatic colorectal cancer patients (mCRC)**. V. Ricci¹, D. Vivenza² ... proposed working mechanism of **cetuximab** is thought to include **antibody-dependent cell-mediated cytotoxicity (ADCC)**. **Cetuximab** has been ...

Genetic and immune factors underlying the efficacy of ...

www.ncbi.nlm.nih.gov > ... > [PubMed Central \(PMC\)](#) ▾ 翻译此页

作者: PA Krawczyk - 2014 - 被引用次数: 2 - 相关文章

2013年11月14日 - Keywords: **cetuximab**, **panitumumab**, **metastatic colorectal cancer**, **mCRC**, ... in **patients with KRAS wild-type gene** (response to treatment was seen ... difficult to **evaluate** the effect of anti-EGFR monoclonal antibodies in this **patient group**. ... **Antibody-dependent cell-mediated cytotoxicity (ADCC)** and ...

KRAS G13D Mutation and Sensitivity to Cetuximab or ...

www.ncbi.nlm.nih.gov > ... > [PubMed Central \(PMC\)](#) ▾ 翻译此页

作者: SS Kumar - 2014 - 被引用次数: 18 - 相关文章

The treatment of metastatic colorectal cancer (mCRC) includes downregulation of